CN103402526B - 组蛋白抑制 - Google Patents

组蛋白抑制 Download PDF

Info

Publication number
CN103402526B
CN103402526B CN201180066031.1A CN201180066031A CN103402526B CN 103402526 B CN103402526 B CN 103402526B CN 201180066031 A CN201180066031 A CN 201180066031A CN 103402526 B CN103402526 B CN 103402526B
Authority
CN
China
Prior art keywords
histones
histone
polyanion
sulfate
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180066031.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103402526A (zh
Inventor
罗斯·温特沃思·斯蒂芬斯
C·R·帕里什
克雷格·杰弗里·弗里曼
蒂莫西·约翰·森登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian National University filed Critical Australian National University
Publication of CN103402526A publication Critical patent/CN103402526A/zh
Application granted granted Critical
Publication of CN103402526B publication Critical patent/CN103402526B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201180066031.1A 2010-12-01 2011-11-29 组蛋白抑制 Active CN103402526B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
US61/418,826 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (2)

Publication Number Publication Date
CN103402526A CN103402526A (zh) 2013-11-20
CN103402526B true CN103402526B (zh) 2016-01-20

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180066031.1A Active CN103402526B (zh) 2010-12-01 2011-11-29 组蛋白抑制

Country Status (15)

Country Link
US (1) US9226939B2 (cg-RX-API-DMAC7.html)
EP (1) EP2646037B1 (cg-RX-API-DMAC7.html)
JP (2) JP2014501730A (cg-RX-API-DMAC7.html)
KR (1) KR101956335B1 (cg-RX-API-DMAC7.html)
CN (1) CN103402526B (cg-RX-API-DMAC7.html)
AU (1) AU2011335881B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013013544B1 (cg-RX-API-DMAC7.html)
CA (1) CA2819642C (cg-RX-API-DMAC7.html)
DK (1) DK2646037T3 (cg-RX-API-DMAC7.html)
ES (1) ES2710857T3 (cg-RX-API-DMAC7.html)
HU (1) HUE043546T2 (cg-RX-API-DMAC7.html)
IL (1) IL226667A (cg-RX-API-DMAC7.html)
NZ (1) NZ611316A (cg-RX-API-DMAC7.html)
SG (1) SG190438A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012071611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11628179B2 (en) * 2017-12-15 2023-04-18 The Australian National University Compounds for treating and preventing extracellular histone mediated pathologies
WO2019246264A1 (en) * 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
CA3130405A1 (en) * 2019-02-25 2020-09-03 The Australian National University Compounds for treating and preventing net associated complications
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药(中国)有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106503A1 (en) * 2002-06-12 2003-12-24 Inalco S.P.A. O-sulphated bacterial polysaccharides and their use
WO2006007392A1 (en) * 2004-06-16 2006-01-19 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006015171A3 (en) * 2004-07-28 2007-01-25 Texas A & M Univ Sys Use of glycosoaminoglycans for the prevention and treatment of sepsis
WO2007013123A8 (en) * 2005-07-28 2007-07-05 Humanitas Mirasole Spa Cyclodextrins for blood detoxification
WO2009061918A1 (en) * 2007-11-06 2009-05-14 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
DE69514059T2 (de) 1994-09-21 2000-05-25 Allrad No. 19 Pty Ltd., Canberra Eine elektrostatische Niederschlagsvorrichtung
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
PT1877105E (pt) 2005-04-29 2013-11-11 Univ Australian Método para formar uma composição radioativa injetável de partículas radioativas encapsuladas em carbono
WO2007062403A2 (en) 2005-11-28 2007-05-31 Vernon D Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
JP5645085B2 (ja) 2008-04-24 2014-12-24 ジ オーストラリアン ナショナル ユニバーシティー マクロ分子を放射性標識化するための方法
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106503A1 (en) * 2002-06-12 2003-12-24 Inalco S.P.A. O-sulphated bacterial polysaccharides and their use
WO2006007392A1 (en) * 2004-06-16 2006-01-19 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006015171A3 (en) * 2004-07-28 2007-01-25 Texas A & M Univ Sys Use of glycosoaminoglycans for the prevention and treatment of sepsis
WO2007013123A8 (en) * 2005-07-28 2007-07-05 Humanitas Mirasole Spa Cyclodextrins for blood detoxification
WO2009061918A1 (en) * 2007-11-06 2009-05-14 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Also Published As

Publication number Publication date
BR112013013544B1 (pt) 2020-09-29
KR20130121877A (ko) 2013-11-06
WO2012071611A1 (en) 2012-06-07
JP2014501730A (ja) 2014-01-23
US9226939B2 (en) 2016-01-05
EP2646037B1 (en) 2019-01-09
IL226667A (en) 2017-02-28
SG190438A1 (en) 2013-07-31
KR101956335B1 (ko) 2019-03-08
ES2710857T3 (es) 2019-04-29
JP2016193917A (ja) 2016-11-17
NZ611316A (en) 2014-12-24
BR112013013544A2 (pt) 2016-10-11
DK2646037T3 (en) 2019-03-04
JP6142039B2 (ja) 2017-06-07
AU2011335881A1 (en) 2013-06-20
HUE043546T2 (hu) 2019-08-28
CN103402526A (zh) 2013-11-20
CA2819642A1 (en) 2012-06-07
CA2819642C (en) 2019-07-16
AU2011335881B2 (en) 2016-07-14
US20130338097A1 (en) 2013-12-19
EP2646037A1 (en) 2013-10-09
EP2646037A4 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
CN103402526A (zh) 组蛋白抑制
CN112437667B (zh) 细胞保护方法和组合物
JPH08508260A (ja) アミロイド症の治療法
JP2005255691A (ja) Gmp−140に特異的な結合を有する糖タンパク質リガンドに対する抗体
JPH11512721A (ja) 炎症反応の軽減のためのヘパリナーゼの使用
KR20120041701A (ko) 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
JP2021517582A (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
JP2015533791A (ja) 骨髄細胞に発現する誘発性受容体1(trem−1)trem様転写産物1(tlt−1)に由来する阻害ペプチドおよびその使用
JPH08501535A (ja) 疾患を治療するためのペプチド薬剤
BRPI0613677A2 (pt) método para tratar doença de célula falsiforme e sequelas da doença de célula falsiforme
US20230083005A1 (en) Methods of killing or inhibiting the growth of cancer cells
JP7402727B2 (ja) リン脂質含有物質安定化剤およびそれを含む体液検査キット
HK1188125B (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
HK1188125A (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
US20250345356A1 (en) Tirapazamine compositions and methods
Rose Investigating The Electrostatics Of Mucins As Key Contributors To Mucus Stasis In Cystic Fibrosis
CN121752271A (zh) 在疾病治疗中使用的稠合哌啶基二环化合物和相关化合物
JP2020515633A (ja) ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用
WO2017007956A1 (en) Compositions and methods for reducing organ rejection by reducing heparan sulfate in donor transplants
CN118615430A (zh) 一种蛋白纳米复合物、含其的靶向递送系统及其应用
JP2004256463A (ja) 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法
Hughes et al. Tourniquet-applied upper limb orthopaedic surgery results in changes to various inflammatory parameters
BR112020013714B1 (pt) Compostos para tratamento e prevenção de patologias mediadas por histona extracelular
Mäkelä Bone marrow-derived stem cell therapy in acute myocardial infarction: an experimental porcine model
Bowden A mannose rich extract reduces inflammation by inhibiting beta (2)-integrins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant